# Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

> **NCT06995508** · PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 66 (estimated)

## Conditions studied

- Cancer-Associated Anorexia
- Head and Neck Squamous Cell Carcinoma
- Neck Squamous Cell Carcinoma of Unknown Primary

## Interventions

- **OTHER:** Best Practice
- **DRUG:** Olanzapine
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06995508
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-24
- **Primary completion:** 2030-11-15
- **Final completion:** 2031-11-15
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06995508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06995508, "Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06995508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*